Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CTI BioPharma Corp. (CTIC)

5.99   0.01 (0.17%) 12-02 16:00
Open: 5.92 Pre. Close: 5.98
High: 6.015 Low: 5.865
Volume: 2,208,383 Market Cap: 760(M)

Technical analysis

as of: 2022-12-02 4:21:56 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 7.21     One year: 8.43
Support: Support1: 5.26    Support2: 4.69
Resistance: Resistance1: 6.17    Resistance2: 7.21
Pivot: 5.81
Moving Average: MA(5): 5.85     MA(20): 5.75
MA(100): 5.82     MA(250): 4.75
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 79.5     %D(3): 73.4
RSI: RSI(14): 57.1
52-week: High: 7.8  Low: 1.76
Average Vol(K): 3-Month: 3,868 (K)  10-Days: 2,575 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CTIC ] has closed below upper band by 24.3%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.02 - 6.05 6.05 - 6.07
Low: 5.79 - 5.82 5.82 - 5.86
Close: 5.94 - 5.99 5.99 - 6.04

Company Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Headline News

Thu, 01 Dec 2022
Heiniger joins Conservation Technology Information Center - Morning Ag Clips -

Wed, 30 Nov 2022
Looking Into CTI BioPharma's Return On Capital Employed - CTI BioPharma (NASDAQ:CTIC) - Benzinga

Wed, 30 Nov 2022
CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit - goskagit.com

Mon, 14 Nov 2022
Premarket Mover: CTI BioPharma Corp (CTIC) Down 2.36% - InvestorsObserver

Wed, 09 Nov 2022
CTI BioPharma Corp (CTIC) Stock: What Does the Chart Say Wednesday? - InvestorsObserver

Mon, 07 Nov 2022
CTI BioPharma Corp. (CTIC) Q3 2022 Results - Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 127 (M)
% Held by Insiders 1.1785e+008 (%)
% Held by Institutions 0.1 (%)
Shares Short 17,430 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.943e+007
EPS Est Next Qtl 0
EPS Est This Year -1.26
EPS Est Next Year -1.88
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -276.9
Return on Assets (ttm) -50.7
Return on Equity (ttm) -1
Qtrly Rev. Growth 3.287e+007
Gross Profit (p.s.) 0
Sales Per Share 23.73
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -96 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0.25
Price to Cash Flow -36.41

Stock Dividends

Dividend 0
Forward Dividend 1.819e+007
Dividend Yield 0%
Dividend Pay Date 2017-01-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.